
GRDN Stock Forecast & Price Target
GRDN Analyst Ratings
Bulls say
Guardian Pharmacy Service is positioned for significant growth due to its differentiated technology capabilities, strong financial flexibility, and robust M&A pipeline. The company's focus on customer service and relationships, along with its expansion into the assisted living and behavioral health markets, provide opportunities for organic growth. With an attractive offering for all stakeholders and potential for market consolidation, we rate GRDN as a Buy with a price target of $47, based on a 2027 adjusted EBITDA multiple in line with the current 2026 multiple.
Bears say
Guardian Pharmacy Service is facing strong competition within their industry and may struggle to gain market share. Additionally, potential regulatory or reimbursement changes and the company's reliance on technology assets could pose risks to their growth and profitability. This, coupled with potential challenges in relationship management with LTCFs and disruptions in their supply chain, may hinder the company's success and lead to a negative outlook for their stock.
This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.
GRDN Analyst Forecast & Price Prediction
Start investing in GRDN
Order type
Buy in
Order amount
Est. shares
0 shares